Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioChemics has entered into research collaboration with Beth Israel Deaconess Medical Center to evaluate the wound healing effects of some of the company's novel, proprietary formulations in preclinical models.
Subscribe to our email newsletter
BioChemics has developed a novel, transdermal drug delivery system that for the first time may allow almost any drug to be efficiently delivered through the skin. The transdermal technology, called VALE (vaso-active lipid encapsulated), may allow a substantial portion of the pharmacopeia to be re-engineered, turning oral drugs into transdermals that are safer (no gastro-intestinal problems), cheaper and potentially faster acting (applied directly to the treated area) than oral equivalents.
John Masiz, president and CEO of BioChemics, said: “We continue to develop new transdermal delivery systems that target a variety of inflammatory and peripheral diseases.”